{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:31:07Z","timestamp":1792161067561,"version":"4.4.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Psychological trauma in childhood can lead to post-traumatic disorder (PTSD) with protracted comorbid depression, which responds poorly to conventional antidepressants. Previous studies have shown that prazosin, an \u03b11-adrenergic receptor antagonist, can help eliminate nightmares and improve sleep quality and suicidal ideation in PTSD patients. This case report presents that prazosin had a rapid antidepressant effect in a female adolescent PTSD patient with treatment-resistant depression (TRD). Prazosin improved not only depression symptoms but also sleep quality, suicidal ideation, and cognitive function. Prazosin was well tolerated without obvious adverse effects. Our preliminary study suggests that further clinical trials are needed to determine the efficacy and safety of prazosin in treating PTSD patients with comorbid TRD.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.803220","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T08:12:34Z","timestamp":1658477554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Prazosin augmentation for treating comorbid treatment-resistant depression and chronic post-traumatic stress disorder"],"prefix":"10.3389","volume":"13","author":[{"given":"Ping","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mincai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1017\/S002196309922481","article-title":"Comorbidity of psychiatric disorders and posttraumatic stress disorder","volume":"61","author":"Brady","year":"2000","journal-title":"J Clin Psychiat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.31887\/DCNS.2015.17.2\/jflory","article-title":"Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations","volume":"17","author":"Flory","year":"2015","journal-title":"Dialogues Clin Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jts.21814","article-title":"The co-occurrence of major depressive disorder among individuals with posttraumatic stress disorder: a meta-analysis","volume":"26","author":"Rytwinski","year":"2013","journal-title":"J Trauma Stress."},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11920-015-0564-2","article-title":"Psychopharmacological strategies in the management of posttraumatic stress disorder (PTSD): what have we learned?","volume":"17","author":"Bernardy","year":"2015","journal-title":"Curr Psychiatry Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1192\/bjp.2020.40","article-title":"Evidence-based prescribing for post-traumatic stress disorder","volume":"216","author":"Bisson","year":"2020","journal-title":"Br J Psychiat."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am J Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.30773\/pi.2020.0411","article-title":"Using prazosin to treat posttraumatic stress disorder and associations: a systematic review","volume":"18","author":"Paiva","year":"2021","journal-title":"Psychiatry Investig."},{"key":"B10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"New England J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jad.2016.10.037","article-title":"A network approach to the comorbidity between posttraumatic stress disorder and major depressive disorder: The role of overlapping symptoms","volume":"208","author":"Afzali","year":"2016","journal-title":"J Affect Diso."},{"key":"B12","doi-asserted-by":"publisher","first-page":"26306","DOI":"10.4088\/PCC.16r01943","article-title":"Efficacy of prazosin in posttraumatic stress disorder: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2016","journal-title":"Primary Care Companion J Clin Psychiatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.sleep.2019.06.010","article-title":"The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis","volume":"67","author":"Zhang","year":"2020","journal-title":"Sleep Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-015-4084-x","article-title":"The development of depression-like behavior is consolidated by IL-6-induced activation of locus coeruleus neurons and IL-1\u03b2-induced elevated leptin levels in mice","volume":"233","author":"Kurosawa","year":"2016","journal-title":"Psychopharmacology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"pyu005","DOI":"10.1093\/ijnp\/pyu005","article-title":"Lipopolysaccharide-induced depressive-like behavior is associated with \u03b11-adrenoceptor dependent downregulation of the membrane GluR1 subunit in the mouse medial prefrontal cortex and ventral tegmental area","volume":"18","author":"Sekio","year":"2015","journal-title":"Int J Neuropsychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.brainresbull.2017.07.011","article-title":"Prelimbic \u03b1(1)-adrenoceptors are involved in the regulation of depressive-like behaviors in the hemiparkinsonian rats","volume":"134","author":"Wu","year":"2017","journal-title":"Brain Res Bull."},{"key":"B17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/JCP.0000000000000638","article-title":"Prazosin in children and adolescents with posttraumatic stress disorder who have nightmares: a systematic review","volume":"37","author":"Akinsanya","year":"2017","journal-title":"J Clin Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.9740\/mhc.2021.03.045","article-title":"Evaluation of low dose prazosin for PTSD-associated nightmares in children and adolescents","volume":"11","author":"Hudson","year":"2021","journal-title":"Mental Health Clin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.mayocp.2012.05.015","article-title":"Treatment of nightmares with prazosin: a systematic review","volume":"87","author":"Kung","year":"2012","journal-title":"Mayo Clinic Proc Mayo Clinic."},{"key":"B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/2045125313500982","article-title":"High-dose prazosin for the treatment of post-traumatic stress disorder","volume":"4","author":"Koola","year":"2014","journal-title":"Therap Adv Psychopharmacol."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.803220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T08:12:37Z","timestamp":1658477557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.803220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":20,"alternative-id":["10.3389\/fpsyt.2022.803220"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.803220","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"article-number":"803220"}}